DK1143955T3 - En kombination af FBPase-inhibitorer og insulinsensibiliseringsmidler til behandling af diabetes - Google Patents
En kombination af FBPase-inhibitorer og insulinsensibiliseringsmidler til behandling af diabetesInfo
- Publication number
- DK1143955T3 DK1143955T3 DK99964313T DK99964313T DK1143955T3 DK 1143955 T3 DK1143955 T3 DK 1143955T3 DK 99964313 T DK99964313 T DK 99964313T DK 99964313 T DK99964313 T DK 99964313T DK 1143955 T3 DK1143955 T3 DK 1143955T3
- Authority
- DK
- Denmark
- Prior art keywords
- diabetes
- treatment
- combination
- insulin
- insulin sensitizers
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Reproductive Health (AREA)
- Child & Adolescent Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11471898P | 1998-12-24 | 1998-12-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1143955T3 true DK1143955T3 (da) | 2005-11-14 |
Family
ID=22357016
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK99964313T DK1143955T3 (da) | 1998-12-24 | 1999-12-22 | En kombination af FBPase-inhibitorer og insulinsensibiliseringsmidler til behandling af diabetes |
Country Status (25)
| Country | Link |
|---|---|
| EP (1) | EP1143955B1 (ko) |
| JP (1) | JP2003515523A (ko) |
| KR (3) | KR100689943B1 (ko) |
| CN (3) | CN100352505C (ko) |
| AT (1) | ATE300288T1 (ko) |
| AU (1) | AU771039B2 (ko) |
| BR (1) | BR9917005A (ko) |
| CA (1) | CA2354053A1 (ko) |
| CZ (1) | CZ20012353A3 (ko) |
| DE (1) | DE69926400T2 (ko) |
| DK (1) | DK1143955T3 (ko) |
| ES (1) | ES2246586T3 (ko) |
| HK (1) | HK1046863B (ko) |
| HU (1) | HUP0402506A3 (ko) |
| ID (1) | ID30237A (ko) |
| IL (2) | IL143569A0 (ko) |
| MX (1) | MXPA01006511A (ko) |
| NO (1) | NO20013115L (ko) |
| NZ (1) | NZ512219A (ko) |
| PL (1) | PL352756A1 (ko) |
| PT (1) | PT1143955E (ko) |
| RU (2) | RU2227749C2 (ko) |
| SK (1) | SK9172001A3 (ko) |
| WO (1) | WO2000038666A2 (ko) |
| ZA (1) | ZA200105016B (ko) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU6452098A (en) | 1997-03-07 | 1998-09-22 | Metabasis Therapeutics, Inc. | Novel purine inhibitors of fructose-1,6-bisphosphatase |
| US6312662B1 (en) | 1998-03-06 | 2001-11-06 | Metabasis Therapeutics, Inc. | Prodrugs phosphorus-containing compounds |
| BR9913532A (pt) | 1998-09-09 | 2001-10-02 | Metabasis Therapeutics Inc | Novos inibidores heteroaromáticos de frutose 1,6-bifosfatase |
| PL356525A1 (en) * | 1999-12-22 | 2004-06-28 | Metabasis Therapeutics, Inc. | Novel bisamidate phosphonate prodrugs |
| IL151248A0 (en) * | 2000-03-08 | 2003-04-10 | Metabasis Therapeutics Inc | Novel aryl fructose-1,6-bisphosphatase inhibitors |
| CA2412142A1 (en) * | 2000-07-06 | 2002-01-17 | Metabasis Therapeutics, Inc. | A combination of fbpase inhibitors and antidiabetic agents useful for the treatment of diabetes |
| AU2002215218A1 (en) * | 2000-11-17 | 2002-05-27 | Takeda Chemical Industries Ltd. | Isoxazole derivatives |
| EP1504014B1 (en) | 2002-05-13 | 2015-12-02 | Metabasis Therapeutics, Inc. | Process for preparation of cyclic prodrugs of pmea and pmpa |
| EP1532157A4 (en) | 2002-05-13 | 2009-02-25 | Metabasis Therapeutics Inc | NEW PRODRUGS FROM PMEA TO PHOSPHONIC ACID BASE AND ITS ANALOG |
| JP4719465B2 (ja) * | 2002-09-04 | 2011-07-06 | ディーエスエム アイピー アセッツ ビー．ブイ． | インスリン感受性増強剤およびペプチド画分を含む栄養補給用および治療用組成物 |
| UA80991C2 (en) | 2002-10-07 | 2007-11-26 | Solid preparation containing an insulin resistance improving drug and an active ingredient useful as a remedy for diabetes | |
| EA009919B1 (ru) * | 2003-02-11 | 2008-04-28 | Вернэлис (Кембридж) Лимитед | Соединения изоксазола |
| CN1902196B (zh) | 2003-12-26 | 2010-12-29 | 协和发酵麒麟株式会社 | 噻唑衍生物 |
| WO2006023515A2 (en) * | 2004-08-18 | 2006-03-02 | Metabasis Therapeutics, Inc. | Novel thiazole inhibitors of fructose 1,6-bisphosphatase |
| CN101119748A (zh) * | 2004-12-13 | 2008-02-06 | 第一三共株式会社 | 用于治疗糖尿病的药物组合物 |
| EP1825854A1 (en) * | 2004-12-15 | 2007-08-29 | Daiichi Sankyo Company, Limited | MEDICINAL COMPOSITION CONTAINING FBPase INHIBITOR |
| EP1889618A4 (en) * | 2005-05-27 | 2010-11-24 | Daiichi Sankyo Co Ltd | COMBINED MEDICINE FOR THE TREATMENT OF DIABETES |
| WO2006137527A1 (ja) | 2005-06-23 | 2006-12-28 | Kyowa Hakko Kogyo Co., Ltd. | チアゾール誘導体 |
| EP2089017A2 (en) | 2006-11-02 | 2009-08-19 | Aestus Therapeutics, Inc. | Methods of treating neuropathic pain by modulation of glycogenolysis or glycolysis pathways |
| CN103665043B (zh) | 2012-08-30 | 2017-11-10 | 江苏豪森药业集团有限公司 | 一种替诺福韦前药及其在医药上的应用 |
| US9631825B2 (en) | 2012-12-18 | 2017-04-25 | Nortek Air Solutions, Llc | Air filter assembly |
| JP2017512183A (ja) | 2014-02-13 | 2017-05-18 | リガンド・ファーマシューティカルズ・インコーポレイテッド | プロドラッグ化合物およびそれらの使用 |
| EP3164136A4 (en) | 2014-07-02 | 2018-04-04 | Ligand Pharmaceuticals, Inc. | Prodrug compounds and uses therof |
| CN105481896A (zh) * | 2015-12-03 | 2016-04-13 | 浙江大学 | 一种地马格列的制备方法 |
| CN113416739B (zh) * | 2021-06-24 | 2022-04-19 | 黑龙江八一农垦大学 | 鲁氏酵母菌基因在提高微生物产hdmf的产量中的应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4968790A (en) * | 1988-08-12 | 1990-11-06 | American Cyanamid Company | Antidiabetic phosphates |
| JPH03157377A (ja) * | 1988-11-18 | 1991-07-05 | Takeda Chem Ind Ltd | チオ尿素誘導体及びａｇｅ生成阻害剤 |
| CA2008325A1 (en) * | 1989-01-24 | 1990-07-24 | Harry E. Gruber | Method and compounds for aica riboside delivery and for lowering blood glucose |
| TW438587B (en) * | 1995-06-20 | 2001-06-07 | Takeda Chemical Industries Ltd | A pharmaceutical composition for prophylaxis and treatment of diabetes |
| US5859037A (en) * | 1997-02-19 | 1999-01-12 | Warner-Lambert Company | Sulfonylurea-glitazone combinations for diabetes |
| WO1998039342A1 (en) * | 1997-03-07 | 1998-09-11 | Metabasis Therapeutics, Inc. | Novel indole and azaindole inhibitors of fructose-1,6-bisphosphatase |
| AU6452098A (en) * | 1997-03-07 | 1998-09-22 | Metabasis Therapeutics, Inc. | Novel purine inhibitors of fructose-1,6-bisphosphatase |
| JP2001515482A (ja) * | 1997-03-07 | 2001-09-18 | メタバシス・セラピューティクス・インコーポレイテッド | フルクトース−１，６−ビスホスファターゼの新規なベンズイミダゾールインヒビター |
-
1999
- 1999-12-22 RU RU2001120726/15A patent/RU2227749C2/ru not_active IP Right Cessation
- 1999-12-22 DE DE69926400T patent/DE69926400T2/de not_active Expired - Lifetime
- 1999-12-22 WO PCT/US1999/030713 patent/WO2000038666A2/en active Application Filing
- 1999-12-22 ID IDW00200101612A patent/ID30237A/id unknown
- 1999-12-22 HU HU0402506A patent/HUP0402506A3/hu active IP Right Revival
- 1999-12-22 JP JP2000590620A patent/JP2003515523A/ja active Pending
- 1999-12-22 AT AT99964313T patent/ATE300288T1/de active
- 1999-12-22 CN CNB998163562A patent/CN100352505C/zh not_active Expired - Fee Related
- 1999-12-22 CN CNA2005100806150A patent/CN1714866A/zh active Pending
- 1999-12-22 KR KR1020017008102A patent/KR100689943B1/ko not_active IP Right Cessation
- 1999-12-22 IL IL14356999A patent/IL143569A0/xx active IP Right Grant
- 1999-12-22 AU AU20583/00A patent/AU771039B2/en not_active Ceased
- 1999-12-22 SK SK917-2001A patent/SK9172001A3/sk unknown
- 1999-12-22 KR KR1020067022095A patent/KR20060114724A/ko not_active Application Discontinuation
- 1999-12-22 DK DK99964313T patent/DK1143955T3/da active
- 1999-12-22 ES ES99964313T patent/ES2246586T3/es not_active Expired - Lifetime
- 1999-12-22 CA CA002354053A patent/CA2354053A1/en not_active Abandoned
- 1999-12-22 BR BR9917005-1A patent/BR9917005A/pt not_active Application Discontinuation
- 1999-12-22 KR KR1020077008649A patent/KR20070046210A/ko not_active Application Discontinuation
- 1999-12-22 EP EP99964313A patent/EP1143955B1/en not_active Expired - Lifetime
- 1999-12-22 PL PL99352756A patent/PL352756A1/xx not_active Application Discontinuation
- 1999-12-22 CZ CZ20012353A patent/CZ20012353A3/cs unknown
- 1999-12-22 PT PT99964313T patent/PT1143955E/pt unknown
- 1999-12-22 NZ NZ512219A patent/NZ512219A/xx not_active IP Right Cessation
- 1999-12-22 CN CNA2007101628889A patent/CN101164618A/zh active Pending
- 1999-12-22 MX MXPA01006511A patent/MXPA01006511A/es active IP Right Grant
-
2001
- 2001-06-05 IL IL143569A patent/IL143569A/en not_active IP Right Cessation
- 2001-06-19 ZA ZA200105016A patent/ZA200105016B/en unknown
- 2001-06-21 NO NO20013115A patent/NO20013115L/no not_active Application Discontinuation
-
2002
- 2002-11-22 HK HK02108475.5A patent/HK1046863B/zh not_active IP Right Cessation
-
2003
- 2003-10-31 RU RU2003132054/14A patent/RU2003132054A/ru not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1143955T3 (da) | En kombination af FBPase-inhibitorer og insulinsensibiliseringsmidler til behandling af diabetes | |
| ATE413386T1 (de) | Ppar-gamma modulatoren | |
| DK1373215T3 (da) | Gelanamycinderivater egnet til behandling af cancer | |
| IL157821A0 (en) | Treatment of type 2 diabetes with inhibitors of dipeptidyl peptidase iv | |
| BR0308928A (pt) | Uso de toxina botulìnica para o tratamento de doenças cardiovasculares, bem como composição para uso em um procedimento cardiovascular | |
| RS20060320A (en) | Substituted indazole-o-glucosides | |
| MY142777A (en) | Substituted indole-o-glucosides | |
| DK1651161T3 (da) | Farmaceutiske præparater og fremgangsmåder til at fremme sårheling | |
| UA87991C2 (en) | Substituted indole-o-glucosides | |
| DK1505990T3 (da) | Fremgangsmåder til behandling af hepatitis | |
| DK1426054T3 (da) | Medicinsk anvendelse af histon-deacetylase-inhibitor og fremgangsmåde til evaluering af antitumor virkning deraf | |
| DK1694354T3 (da) | Fremgangsmåde til at forhindre og behandle diabetes ved anvendelse af neurturin | |
| DK1865990T3 (da) | Fremgangsmåde til behandling af type 2 diabetes | |
| NO20003813L (no) | FremgangsmÕter for Õ redusere eller forhindre smerte ved bruk av spicamycin eller derivater derav | |
| WO2003103597A3 (en) | DIAGNOSIS AND TREATMENT OF DIABETES AND INSULIN RESISTANCE | |
| DE60319681D1 (de) | Zytokapazität-verfahren | |
| DE69924385D1 (de) | Verwendung von angiotensin zur behandlung von krebsmetastasierung | |
| RS20060323A (en) | Substituted indole-o-glucosides |